Propanc Biopharma, Inc. PPCB
Set alert
1.84 USD -0.27 -12.80%
At close · Oct 30
1.89 +0.05 +2.51%
After hours · Oct 30, 7:06 PM ET
1.82 Day range 2.13
1.84 52-week range 310.00
- YTD
- -98.63%
- 1 year
- -99.41%
- Open
- 1.91
- Prev close
- 2.11
- Mkt cap
- 1.90M
- Vol
- 65.61K
- Avg vol
- 188.07K
- EPS
- -176.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.82
- High
- 2.13
- Earnings
- Sep 27, 2023
Next earnings
Sep 27, 2023
Expected Sep 27, 2023. Consensus EPS estimate 0.00.
Financials — quick view
PPCB Revenue — quarterly 0
PPCB Net income — quarterly -4.57M
PPCB EPS — quarterly 62.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Feb 20, 2024 | Dec 1, 2023 | 0.00 | -0.03 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Sep 27, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
News
- Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
- Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation
- Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
- Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%
- Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
- CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
- Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26
- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
- Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer
- Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
Your note
Sign in to keep a note on PPCB — it syncs with the Stock Master app.